Status:
RECRUITING
TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients
Lead Sponsor:
Chiesi Poland Sp. z o.o.
Collaborating Sponsors:
Gesellschaft für Therapieforschung mbH
Conditions:
Asthma
Eligibility:
All Genders
Brief Summary
TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS/LABA/LAMA single-inhaler triple therapy in a real-world ...
Detailed Description
The goals of asthma therapy for all degrees of disease severity are minimising asthma symptoms, maximising lung function, and preventing asthma exacer-bations. Despite the existing treatment options a...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years of age,
- Patients with confirmed leading diagnosis of asthma with or without concomitant COPD,
- Physician decision to start fixed triple therapy with ICS/LABA/LAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS,
- Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study.
Exclusion
- • Participation in an interventional clinical trial within 30 days prior to en-rolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06567977
Start Date
August 1 2024
End Date
August 1 2025
Last Update
August 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indywidualna Specjalistyczna Praktyka Lekarska
Tarnowskie Góry, Poland, 42-609